Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2025 05:17 ET | Source: Research and Markets

Endometriosis Global Clinical Trials Market Review 2025 | Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The "Endometriosis - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report...
May 22, 2025 09:41 ET | Source: Research and Markets

CD40 Targeted Therapies Market Research Report 2025: Clinical Trials, Therapeutic Approaches & Market Opportunities to 2027 - Competition Heats Up with 20+ Therapies in Advanced Stage

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025" has been added to ResearchAndMarkets.com's...
April 17, 2025 05:54 ET | Source: Research and Markets

Clinical Trial Services Research Report 2025: Oncology, Neurology, Dermatology, CVD, Laboratory, Monitoring, Recruitment, PV, Data Management - Global Forecast to 2030

Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- "Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology,...
April 03, 2025 08:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
April 02, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
March 27, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
February 28, 2025 04:06 ET | Source: Research and Markets

Saudi Arabia Targets the $200 Million Clinical Trials Market with Over 400 Studies Underway

Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Clinical Trials Market, Ongoing Clinical Trials by Company, Indication, Phase & Regulations Insight 2025" report has been added to ...
January 29, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 23, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 14, 2025 10:55 ET | Source: Research and Markets

Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies

Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Clinical Trials Support Services Market Size, Share & Trends Analysis Report By Phases, By Service, By Sponsor, By Region, And Segment Forecasts,...

Next Page keyboard_arrow_right